Continued access to lorcaserin for Dravet syndrome and hard-to-treat epilepsy
Part of Brain & nervous system clinical trials.
This trial provides continued access to lorcaserin, a study drug that may help reduce seizures in people with Dravet syndrome or other hard-to-treat epilepsies. It's for people who are already taking the drug and finding it helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Dravet syndrome or another type of epilepsy that hasn't improved with standard treatments.
- You must be at least 2 years old.
- You must already be taking lorcaserin for epilepsy, and you must have started it before February 13, 2020, OR you must have completed a specific earlier study (called E2023-A001-304).
- Your doctor must agree that lorcaserin is helping your seizures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This study tests whether a cannabis-based medicine can reduce seizures in people with epilepsy that hasn't improved with other treatments. It may offer a new option for those who continue to have seizures.
This study tests a personalized, non-invasive brain stimulation method called tDCS for people with drug-resistant epilepsy that starts in one part of the brain. It aims to reduce seizures in those who cannot have surgery or have not been helped by surgery.
This Phase 3 study tests EPX-100 (clemizole) to help reduce seizures in people with Dravet syndrome whose seizures are not fully controlled by current anti-seizure medicines. You may consider this study if your Dravet diagnosis is confirmed and your medical situation fits the specific rules about medicines and seizure causes.
This program lets people who have already finished a clinical trial of the study drug LP352 and are still getting benefit from it keep receiving it. It's designed for those with developmental epileptic encephalopathy (a type of epilepsy that starts in childhood and affects development).
This trial tests if the drug sirolimus can help people with focal seizures (starting in one part of the brain) that don't improve with at least two other medications. It aims to reduce seizure frequency in adults aged 18 to 60.
Hear when a new Drug Resistant Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.